TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of Complete Response (CR) post ASCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Health related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Serum Urate Level <6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of total antibiotic exposure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of subjects with decreased body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of quantitative stenosis grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Success based on the Harris Hip Scoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Survived
Endpoint domain: Mortality/survival
Primary endpoint: Change in Patient-Reported Arthralgia Inventory (PRAI) Measure for Joint Arthralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Brief Pain Inventory Short Form (BPI SF) Measure for Body Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brief Pain Inventory Short Form (BPI SF) Measure for Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Measure for Pain, Stiffness, and Physical Function of Knee and Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ocular Discomfort Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival Fluorescein Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperphagia Questionnaire (HQ)- Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in MGFA Quantitative MG Score for Disease Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified King's Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Alert acceptance rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in function of lipid rafts in immune cell membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Agreement between algorithm prediction and NGS analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain structure, function and chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual acuity after repair of open globe injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants completing objective outcome measurements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cognitive/Memory score for CANTAB test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance on Stroop test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance on Trail making test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction of BK Viruria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clearance of BK Viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relative Node Detection Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passage of stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Minute Ventilation to Carbon Dioxide Production (VE/VCO2) Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pre-operative Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of 18F-DCFPyL PET/CT imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacokinetics of oblimersen (G3139)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Appropriate ICD therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of Granzyme B (GzmB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cefotaxim serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI microbial community composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GI microbiome diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from Baseline in Headache Impact Test
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in anxious ruminations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of acute exacerbation of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Subjects Without a Treatment Related Severe Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Colorectal cancer (CRC) screening rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of failure to provide a FIT kit to an eligible patient making a clinic visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Return rate of completed FIT kits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence Rate of Major Adverse Cardiovascular Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with behaviors suggestive of misuse, diversion, abuse and/or addiction
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Glucose maximal concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immune-related progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Renal or Hepatic dysfunction and Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants with Severe Infusion Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Regimen Related Death
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Severe Cytokine Release Syndrome (CRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Recording and evaluating LFPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: successful implantation of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: measured glomerular filtration rate (mGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in LDL-Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Treatment-related Adverse Events with a Severity of 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in total nasal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver Allograft Loss
Endpoint domain: Mortality/survival
Primary endpoint: Need for Transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants reporting Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: CTC markers level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neonatal health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in frequency of peripheral immune cell populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in activation status of peripheral immune cell populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: chronic moderate-to-severe post-surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSPedi Total Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Physical Activity After 12 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility of Physical Activity After 26 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility of Physical Activity After 52 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Stone size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crushing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Troma in the ureter area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the Sunstone IPL device
Endpoint domain: Adverse events/effects
Primary endpoint: Short-term hair reduction (1 month after treatment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term hair reduction (3 months after treatment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perfusion within enhancing tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in peak velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection and Infestations Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Naso-endoscopy views using NOHL score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Retention in Treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Brief Addiction Monitor questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive Outcomes Measures Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the concentration-time curve (AUC) for RO4917838
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) for valproate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Adverse Events Other Than Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain when insulin injection
Endpoint domain: Adverse events/effects
Primary endpoint: Verbal Pain Score With Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 (lt): Forced Expiratory Volume in 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FVC(lt): Forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PEF(lt/sn): Peak expiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Mechanical Hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Temporal Summation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Conditioned pain modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with steroid free clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal calprotectin <250µg/g
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index of reorganization of the structural hubs (ks-Degree)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: clinical and biological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Pulmonary Exacerbation Requiring IV Antibiotics or Hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive function as measured by ADAS-Cog-K
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: presence of residual tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complete response in patients with high-risk Myelodysplastic Syndrome (MDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prostate-specific antigen (PSA) response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: True Positive Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False Positive Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in left atrial volume index (LAVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Yale Global Tic Severity Scale Total Tic Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in CAHI1 and CAHI2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prescription opioid misuse
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of DRE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adult ADHD Investigator Symptom Rating Score (AISRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with at least one MAGE-A3 gene SNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good response to treatment as measured on MRI (mrTRG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with Symptomatic Intracranial Hemorrhage (SICH) or new infarct within 24 (±12) hours post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of participants with a new occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of participants with a TICI Score ≥IIb post procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fracture union time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average monthly enrollment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Compliance with study treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of complete follow-up at 6 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ocular Surface Disease Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of regorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tenofovir-diphosphate (TFV-DP) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fold changes of microRNAs in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fold changes of proteins in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of Metlin & Metlos Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Endothelium-dependent Flow Mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Center for Epidemiologic Studies - Depression (CES-D) scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proteomic profile analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum level of reproductive hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to tumor relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: mean quality-adjusted life year (QALY) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Risk score from RetnaGene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk score from Macula Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fat mass percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in resting heart rate from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in resting blood pressure from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in fasted blood triglyceride concentration from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fasted blood cholesterol from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in blood c-reactive protein concentration from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Timed up and go - version for the visually impaired (TUG-LV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Unmedicated Diurnal Intraocular Pressure (DIOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Area under the LDH concentration-time curve (LDH AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of women participating in the program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Functional Impairment Test-Head and Neck, Shoulder, Arm (FIT-HaNSA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of subjects improving in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Related and Unrelated Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to 25% decrease in JCY-BOCS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular wall motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of JNJ-40346427
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics (PK) of JNJ-40346427
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving MCID Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adjudicated Target Lesion Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensory Organization Test - Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse wave velocity (PWV) stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: disease control rate (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Total Infection Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 dose (RP2D)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Realistic expectations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of LGA (Large for Gestational Age)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Pain Interference on Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time and assistive level to negotiate stairs, ramps, curbs, and turning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Assessment of Scalp Coverage
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disabilities of the Arm, Shoulder, and Hand (DASH) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recurrences of pelvic organ prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from 3 months to 9 months Post-Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes